# Study of ASN51 in Adults With Early Alzheimer's Disease

> **NCT06677203** · PHASE2 · TERMINATED · sponsor: **Asceneuron S.A.** · enrollment: 123 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** ASN51
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06677203
- **Lead sponsor:** Asceneuron S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-16
- **Primary completion:** 2024-11-08
- **Final completion:** 2024-11-08
- **Target enrollment:** 123 (ACTUAL)
- **Why stopped:** Strategic decision
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677203, "Study of ASN51 in Adults With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06677203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*